Back to search

National and Kapodistrian University of Athens

Investigation of the role of inotropy in doxorubicin induced cardiotoxicity

Abstract

dc:description

The antitumor agent doxorubicin (DXR) can cause cardiomyopathy and heart failure (HF). Levosimendan (LEVO) is a drug clinically used for the treatment of HF. However, the underlying mechanism of LEVO on DXR cardiotoxicity is unknown.Aim: We investigated i. the effect of different doses of LEVO on acute DXR cardiotoxicity, ii. its effects after repeated and/or single administration on sub-chronic DXR cardiotoxicity in rats, iii. The underlying signaling mechanisms, iv. its effects on phospholamban knockout mice (PLN KO) and v. its effects on an in vivo MMTV-Neu murine breast cancer (BC) model of chronic DXR cardiotoxicity.Methods: Initially, prostate cancer (PC3) cell line was treated with a wide range of DXR and LEVO concentrations either alone or in combination, in order to investigate a possible interaction between LEVO and DXR as far as the cytotoxicity of the latter is concerned. Subsequently, Wistar male rats were randomly assigned into 5 groups for acute [Control (N/S 0.9%), DXR (20mg/kg), DXR+LEVOA (LEVO at 12μg/kg) and DXR+LEVOB (LEVO at 24μg/kg), DXR+LEVOB+5HD (5HD at 40 mg/kg), interventions were performed for 3 consecutive days] and 6 groups for sub-chronic DXR cardiotoxicity [Control (N/S 0.9%), DXR (18mg/kg divided in 4 equal doses), DXR+LEVO (LEVO at 24 μg/kg divided in 4 equal doses), DXR+LEVO+5HD (5HD at 40 mg/kg on alternate days) DXR+LEVO(ac) (LEVO acutely at 24 μg/kg), DXR+LEVO(ac)+5HD (5HD at 40 mg/kg on alternate days), interventions were performed for 14 consecutive days]. Histological and molecular analysis was performed in all the aforementioned protocols. PLN ΚΟ mice were divided in 2 groups [PLN ΚΟ DXR (18mg/kg) and PLN ΚΟ DXR+LEVO(ac) (LEVO acutely at 24 μg/kg), interventions were performed for 14 consecutive days]; Female BC mice in 4 groups [Control, DXR (18mg/kg), DXR+LEVO(ac) (LEVO acutely at 24 μg/kg) and LEVO(ac), interventions were performed for 28 consecutive days]. Cardiac function was assessed echocardiographically in all the above protocolsResults: In the in vitro experiments on the PC3 cell line, when LEVO co-administered with DXR it did not abrogate DXR antitumor potency. On the contrary a possible synergy between the two compounds was evident. In the acute DXR cardiotoxicity protocol, LEVO reduced morphological changes (namely vacuolization, focal disruption of myocardial fibers and mononuclear cell infiltration) at both doses. Moreover, it dose-dependently reduced malondialdehyde (MDA) and protein carbonyls (PCs) while it decreased MMP2 mRNA expression at the high dose. Only LEVO at the highest dose regulated oxidative stress related proteins, as presented by the decrease in iNOS and NOX4 and led to an increase in Akt, eNOS and AMPK phosphorylation. In the sub-chronic DXR cardiotoxicity protocol, the single bolus dose of LEVO favorably restored myocardial contractility and abrogated morphological DXR-induced cardiac defects (namely vacuolization and mononuclear cell infiltration). Single-dose and repeated administration of LEVO presented the same antioxidant potency as far as reduction of MDA, PCs, iNOS and NOX-4 are concerned, as well as upregulated MnSOD. However, only the single dose of LEVO led to a phosphorylation of Akt, eNOS and AMPK and activation of cGMP-PKG and cAMP-PKA axis as shown by elevated cGMP and cAMP levels and VASP phopshorylation. Consecutively, only the single dose of LEVO led to the phosphorylation of phospholamban (PLN). On the contrary single dose-LEVO, did not presented any beneficial effects on PLN-KO mice, a fact revealing the pivotal role of PLN in LEVO cardioprotective effect. Finally, in the murine model of BC mice, LEVO abrogated BC cardiac dysfunction induced by sub-chronic DXR induced cardiomyopathy and increased survival. Conclusions: Single-dose LEVO prevented DXR cardiomyopathy through cGMP/cAMP-PLN pathways. highlighting the role of inotropic stimulation in DXR cardiotoxicity and providing the grounds for further clinical testing of LEVO in this setting.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2018

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Efentakis, Panagiotis
  • Εφεντάκης, Παναγιώτης

Subjects

dc:subject × 16

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/43387

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Efentakis, Panagiotis; Εφεντάκης, Παναγιώτης. Investigation of the role of inotropy in doxorubicin induced cardiotoxicity. National and Kapodistrian University of Athens, 2018. http://hdl.handle.net/10442/hedi/43387